Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Clinical trial NCT01931098 · COMPLETED

Trial details

NCT number: NCT01931098
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma Glioblastoma Multiforme Gliosarcoma Brain Neoplasms Central Nervous System Neoplasms

Start date: 2015-12-10
Primary completion: 2019-09-12
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.